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The effect of 12-tetradecanoyl phorbol 13-acetate (TPA) on the hormonal modulation of adenylate cyclase was studied. The effect of epinephrine 
(a,-adrenergic action) was markedly diminished in membranes from TPA-treated platelets as compared to the controls. Interestingly, the inhibitory 
effect of guanylyl imido diphosphate (Gpp(NH)p) was not altered. Neither the number of 3-adrenoceptors nor their affinity for PH]yohimbine 
were affected by the treatment with TPA. In control platelets, 77% of the receptors were in a high-affinity state for epinephrine and 22% in a low- 
affinity state; Gpp(NH)p shifted the receptor affinity towards the low-affinity conformation. In membranes from TPA-treated platelets, the receptors 
were in the low-affinity state and no further decrease in affinity was induced by Gpp(NH)p. Our data suggest hat activation of protein kinase 
C in platelets blocks the hormonal inhibition of adenylate cyclase by interfering with the receptor-G, interaction. 
Protein kinase C; Enzyme activation; Receptor-protein interaction; Adrenoceptor 
1. INTRODUCTION 
Protein kinase C participates in the intracellular pro- 
pagation of signals that act through the calcium- 
phosphoinositide transduction system [ 11. However, its 
importance goes much beyond this, protein kinase C 
provides positive forward as well as negative feedback 
controls over various steps of its own and other signall- 
ing pathways [2]. 
The adenylate cyclase complex (receptors, G-proteins 
and the catalytic subunit) seems to be a target of pro- 
tein kinase C and thus, one of the sites through which 
major interaction between these two signalling 
pathways takes place [2]. It has been observed that ac- 
tivation of protein kinase C modulates the activation of 
adenylate cyclase induced by hormones and 
neurotransmitters [3-51 and impairment of the 
hormone-sensitive inhibitory pathway of adenylate 
cyclase by protein kinase C has been reported [6-91. 
Treatment of human platelets with 1Ztetradecanoyl 
phorbol 13-acetate (TPA) largely impairs the GTP- 
dependent hormone-sensitive inhibitory pathway to 
adenylate cyclase which involves the inhibitory GTP- 
binding protein, Gi [6-91. Protein kinase C 
phosphorylates Gi [7] and suppresses its function in 
hormonal inhibition of adenylate cyclase [6-91. 
Guanine nucleotide-binding proteins seem to exert 
two basic functions: first, to regulate the activity of 
membrane effecters (i.e. to activate or inhibit enzymes, 
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such as adenylate cyclase phospholipase A2 or 
phospholipase C and ionic channels) [lo, 1 I] and se- 
cond, to modulate the affinity state of hormone recep- 
tors [12]. 
Using human platelets we examined the effect of 
TPA on these two functions of Gi; our results suggest 
that activation of protein kinase C uncouples Gi from 
the cuz-adrenoceptors without altering the interaction of 
Gi with adenylate cyclase. 
2. MATERIALS AND METHODS 
Blood was obtained from healthy men and women who had taken 
no medication during the previous 2 weeks. Platelet-rich plasma was 
obtained by centrifugation. In some experiments the platelet-rich 
plasma was incubated with 1 mM aspirin for 30 min at 37°C to in- 
hibit cyclooxygenase [13]; this treatment did not alter the results ob- 
tained. After a preequilibration period of 5 min at 37°C the platelets 
were challenged with 1 CM TPA, or vehicle for 1 min; the platelets 
were centrifuged and homogenized. A crude membrane preparation 
was obtained as described by Hoffman et al. [14]. 
Adenylate cyclase activity was assayed in a mixture containing 
25 mM Tris (pH 7.5), 5 mM MgClz, 0.1 mM ATP (containing 
[~u-~‘P]ATP 500000 cpm per tube), 5 mM theophylline, 2.5 mg/ml 
phosphocreatine and 1 mg/ml creatine kinase; the reaction was 
started by the addition of membrane protein (50 pg) and it was car- 
ried out for 20 min at 30°C in a total volume of 0.1 ml. Cyclic AMP 
was isolated by the method of Salomon et al. [15]. 
[3H]Yohimbine binding studies were performed as described by 
Hoffman et al. [14]. The binding competition experiments were 
analyzed by computer modelling techniques [15- 171. 
3. RESULTS 
Basal adenylate cyclase activity was similar in mem- 
branes from control and TPA-treated platelets (26 f 6 
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Fig. 1. Effect of TPA on the stimulation of adenylate cyclase activity 
by forskolin. Membranes from control (open circles) or TPA-treated 
(closed circles) platelets were incubated with different concentrations 
of forskolin. Results are expressed as % of basal activities. Plotted 
are the means and vertical ines represent he SE of 6 experiments in 
triplicate using different membrane preparations. 
and 25 Z!Z 5 pmob’min per mg protein for membranes 
for control and TPA-treated platelets, respectively 
(means f SE, n = 10)). Forskolin stimulated adenylate 
cyclase activity in a dose-dependent fashion in mem- 
branes from control and TPA-treated platelets (fig.1). 
However, the activation induced by the diterpene was 
slightly greater in membranes from TPA-treated 
platelets than in the controls (fig. 1). Epinephrine induc- 
ed a dose-dependent inhibition of forskolin-stimulated 
adenylate cyclase activity (fig.2); the effect of 
epinephrine was blocked by 10gM yohimbine in- 
dicating the involvement of az-adrenoceptors (not 
shown). In agreement with the data of Jakobs et al. [6], 
we observed that the effect of epinephrine was marked- 
-LOO [Epinephrine] M -Lo@ [Gpp(NH)pJ M 
Fig.2. Effects of epinephrine or GppfNHfp on forskolin-stimulated 
adenylate cyclase activity. Membranes from control (open circles) or 
TPA-treated (closed circles) platelets were incubated with 1OOpM 
forskolin and either 1OrM GTP and different concentrations of 
epinephrine (left panel) or different concentrations of Gpp(NH)p 
(right panel). Results are expressed as % of the adenylate cyclase 
activity observed in &he presence of forskolin alone. Piotted are the 
means and vertical lines represent the SE of 10 experiments in 
-LOG [Epmephrine) M 
Fig.3. Displacement by epinephrine of specific 13H]yohimbine 
binding. Membranes from control (open symbols) or TPA-treated 
platelets (solid symbols) were incubated with 7 nM 13H]yohimbine 
and different concentrations of (-)epinephrine in the absence 
(circles) or presence (triangles) of lOOpM Gpp(NH)p. Plotted is a 
representative xperiment of 6 replicates with different membrane 
preparations. The insets show the Hill analysis of the competition 
triplicate using different membrane preparations. studies. 
Table 1 
Effect of TPA on [3H]yohimbine binding 
Treatment B IIXllX 
(fmol/mg per protein) (2) 
Control 118 rt 10 3.2 + 0.3 
TPA 140 4 19 3.5 zt 0.3 
Membranes from control or TPA-treated platelets were incubated 
with [3HJyohimb~ne as described in section 2. Results are the 
means i. SE from 3 separate xperiments in triplicate 
ly reduced in membranes from TPA-treated platelets as 
compared to the controls, i.e. IOOpM epinephrine in- 
duced a 35-40070 inhibition of adenylate cyclase activity 
in control membranes whereas in membranes from 
TPA-treated platelets the same concentration of 
epinephrine induced only a 5-100/o inhibition (fig.2). 
The effect of the treatment with TPA was not exclusive 
for epinephrine. The action of other agents that inhibit 
adenylate cyclase through their own receptors such as 
thrombin and platelet activating factor (PAF) was also 
similarly diminished (data not shown). Interestingly, 
the inhibitory action of the hydrolysis resistant 
analogue of GTP, Gpp(NH)p, was identical in mem- 
branes from control and TPA-treated platelets (fig.2). 
We next examined the effect of TPA treatment on 
the a2-adrenoceptor number and affinity using 
[3H]yohimbine. Scatchard plots of the binding data 
were linear, consistent with a single type of receptor; no 
significant difference in Bma, or & was observed bet- 
ween controI membranes and those from TPA-treated 
platelets (table 1). The data indicate that neither the 
number of sites nor their affinity for the antagonist is 
altered by the treatment with TPA. 
In membranes from control platelets, the displace- 
ment of [3H]yohimbine binding by epinephrine was 
dose-dependent (fig.3) and gave a shallow curve with a 
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Table 2 
Parameters derived from the computer model&g of competition curves of epinephrine with 
[3H]yohimbine 
Treatment Agents [3H]Yohimbine 
KI (nM) 070 KZ (W VO Hill coefficient 
Control epinephrine= 20 * 20 71 Ik 5 3000*700 22 f 6 0.45 zk 0.03 
epinephrine + Gpp(NH)p - _ 2000*100 100 0.72 +- 0.02b 
TPA epinephrine - - 1700 f 100 100 0.74 + 0.04 
epinephrine + Gpp(NH)p - _ 1800 It 200 100 0.72 + 0.04 
a Two-state fit significantly better than one-state fit (P < 0.05) 
b P < 0.001 as compared to epinephrine alone, control 
Results are the means f SE of 6 experiments in triplicate using different membrane preparations 
November 1989 
Hill coefficient of 0.45, which suggests the presence of 
heterogeneous binding sites. Addition of 0.1 mM 
Gpp(NH)p induced an approximately 30-fold shift to 
the right in the displacement curve and an increase in 
the Hill slope to 0.72 (fig.3). This Hill slope suggests 
that some heterogeneity may still persist in the binding 
sites; similar results have been observed by other 
authors [18] but the reason is unknown. Computer 
modelling of the data indicated in the absence of 
Gpp(NH)p the presence of two classes of binding sites 
with high (Kl) and low (I(r) affinities for epinephrine 
(table 2); most of the receptors were in the high-affinity 
state for agonists. The competition curve in the 
presence of Gpp(NH)p gave a binding isotherm consis- 
tent with a single class of binding sites whose affinity 
for epinephrine was similar to the & observed in the 
absence of Gpp(NH)p (table 2). 
The displacement of [‘Hlyohimbine binding by 
epinephrine in membranes from TPA-treated platelets 
showed two important differences with the controls 
(fig.3): first, the displacement curve in the absence of 
Gpp(N~)p was steeper (Hill, 0.74) and shifted to the 
right; second, no further effect of Gpp(NH)p was 
observed (fig.3). Computer modelling indicated that in 
these membranes a single type of snes was detected 
regardless of the presence or absence of Gpp(NH)p 
(table 2). 
4. DISCUSSION 
Our present data confirm and extend those of Jakobs 
and co-workers [6-91 and indicate that activation of 
protein kinase C leads to an impairment of the 
hormone-sensitive inhibitory branch of adenylate 
cyclase. The alteration of the inhibitory branch of 
adenylate cyclase was observed for three agents 
(epinephrine, PAF, thrombin) acting through indepen- 
dent receptors. These data are consistent with the idea 
that the coupling between these receptors and the 
catalytic subunit of adenylate cyclase is affected by pro- 
tein kinase C; such coupling is mediated via the in- 
hibitory guanine nucleotide-binding regulatory protein, 
Gi. 
Interestingly, the inhibitory effect of Gpp(NH)p on 
forskolin-stimulated adenylate cyclase activity was not 
altered in membranes from TPA-treated platelets, 
which suggest hat the mechanism(s) through which Gi 
inhibits adenylate cyclase are not altered by protein 
kinase C. In other words, the data suggest that the 
alteration induced by protein kinase C on Gi does not 
affect its interaction with the catalytic subunit of 
adenylate cyclase but rather that it is the receptor-Gi n- 
teraction that is affected. Direct evidence for an altered 
receptor-Gi interaction was obtained in the binding 
studies. However, the possibility of an additional 
defect in the Gi-adenylate cyclase interaction cannot be 
completely ruled out. Two reasons exist for such 
reserve: (i) firstly, our understanding of the 
mechanism(s) through which adenylate cyclase is in- 
hibited by Gi is incomplete [ 19-211 and (ii) secondly, it 
is not known if the mechanisms of activation of Gi by 
hydrolysis resistant analogues of GTP are identical to 
those of the natural nucleotide. Regarding this latter 
point, GTP has a biphasic effect on human platelet 
adenylate cyclase, increasing enzyme activity at sub- 
micromolar concentrations and inducing inhibition at 
higher concentrations [S]; TPA blocks the inhibitory 
phase of GTP action [8]. However, hydrolysis-resistant 
analogues of GTP, such as GTP[S] or Gpp(NH)p (this 
manuscript), inhibit adenylate cyclase similarly in 
membranes from control and TPA-treated platelets. 
There is evidence that many receptors including 
cy2-adrenoceptors exist in two interconvertible affinity 
states for agonists (high- and low-affinity states). The 
conversion of the Low-affinity state to the high-affinity 
state seems to involve the interaction with G-proteins; 
reconstitution of the high-affinity state for agonists of 
platelet crz-adrenoceptors with exogenous Gi has 
already been reported [22]. Our binding data indicate 
that in membranes from TPA-treated platelets, 
azuz-adrenoceptors remain in the low-affinity state for 
agonists which suggests that the receptor-Gi interaction 
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Volume 257, number 2 FEBS LETTERS November 1989 
is perturbed by pretreatment with TPA and that 
therefore the cYz-adrenoceptors are unable to form the 
high-affinity state for agonists. Remarkable similarities 
exist between the effects of TPA on platelets reported 
here and those of pertussis toxin on other cells. 
Acknowledgements: The authors thank MS Guadalupe Ramirez for 
typing the manuscript. The authors also thank the blood donors and 
Miss Lucia Yafiez for obtaining the blood samples. This research was 
supported in part by grants from CONACyT (ICEXCNA 060394) 
The Third World Academy of Sciences (TWAS RGBC 88-93) and 
Fundacibn Miguel Aleman. 
REFERENCES 
[1] Nishizuka, Y. (1984) Science 225, 1365-1370. 
[2] Nishizuka, Y. (1986) Science 233, 305-312. 
[3] Sugden, D., Vanecek, J., Klein, D.C., Thomas, T.P. and 
Anderson, W.B. (1985) Nature 314, 359-361. 
[4] Yoshimasa, T., Sibley, D.R., Bouvier, M., Lefkowitz, R.J. and 
Caron, M.G. (1987) Nature 327, 67-70. 
[5] Garcia-Sdinz, J.A., Mendlovic, F. and Martinez-Olmedo, 
M.A. (1985) Biochem. J. 228, 277-280. 
[6] Jakobs, K.H., Bauer, S. and Watanabe, Y. (1985) Eur. J. Bio- 
them. 151, 425-430. 
[71 
181 
[91 
DOI 
[ill 
WI 
[I31 
1141 
1151 
[I61 
iI71 
1181 
u91 
PO1 
[211 
WI 
Katada, T., Gilman, A.G., Watanabe, Y., Bauer, S. and 
Jakobs, K.H. (1985) Eur. J. Biochem. 151, 431-437. 
Watanabe, Y., Horn, F., Bauer, S. and Jakobs, K.H. (1985) 
FEBS Lett. 192, 23-27. 
Bauer, S. and Jakobs, K.H. (1986) FEBS Lett. 198, 43-46. 
Gilman, A.G. (1987) Annu. Rev. Biochem. 56, 615-649. 
lyengar, R. and Birnbaumer, L. (1987) IS1 Atlas of Science 1, 
213-221. 
Ross, E.M., Magure, M.E., Sturgill, T.W., Biltonen, R.L. and 
Gilman, A.G. (1977) J. Biol. Chem. 252, 5761-5775. 
Burch, J.W., Stanford, N. and Majerus, P.W. (1978) J. Clin. 
Invest. 61, 314-319. 
Hoffman, B.B., Michel, T., Breenneman, T.B. and Lefkowitz, 
R.J. (1982) Endocrinology 110, 926-932. 
Salomon, Y., Londos, C. and Rodbell, M. (1974) Anal. 
Biochem. 58, 541-548. 
DeLean, A., Munson, P.J. and Lefkowitz, R.J. (1978) Am. J. 
Physiol. 235, E97-E102. 
Hoffman, B.B., Mullikin-Kilpatrick, D. and Lefkowitz, R.J. 
(1980) J. Biol. Chem. 255, 4645-4652. 
Neubig, R.R., Gantzos, R.D. and Thomsen, W.J. (1988) 
Biochemistry 27, 2374-2384. 
Katada, T., Bokoch, G.M., Smigel, M.D., Ui, M. and Gilman, 
A.G. (1984) J. Biol. Chem. 259, 3586-3595. 
Hildebrandt, J.D., Codina, J. and Birnbaumer, L. (1984) J. 
Biol. Chem. 259, 13178-13185. 
Toro, J.M., Montoya, E. and Birnbaumer, L. (1987) Mol. 
Endocrinol. 1, 669-676. 
Kim, M.H. and Neubig, R.R. (1987) Biochemistry 26, 
3664-3672. 
430 
